Triple negative breast cancer (TNBC) is an aggressive type of heterogeneous phenotype based diseases, which are specified by absences of receptors expressions such as Progesterone Receptor (PR), Estrogen Receptor (ER), and Human Epidermal Growth Factor Receptor 2 (HER2) [1]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.